



18 **ABSTRACT**

19

20 Allogeneic hematopoietic cell transplantation (alloHCT) is a vital therapy for various  
21 hematologic diseases, though it demands high physiological resilience. Frailty, a syndrome  
22 impacting the body's ability to withstand stress, affects outcomes of alloHCT across all ages.  
23 This study examines the relationship between frailty and peri-transplant activity and sleep  
24 patterns using Fitbit® devices. In this pilot study, adults scheduled for their first myeloablative  
25 alloHCT at the University of Minnesota from June 2022 to January 2023 were included if they  
26 had a compatible device for the Fitbit® app. Participants were monitored for activity and sleep  
27 from admission to day +30 post-transplant. Frailty was assessed pre-transplant using Fried  
28 Phenotype criteria. Data were analyzed for activity and sleep patterns differences among not  
29 frail, pre-frail, and frail groups. Nine patients provided sufficient data for analysis, showing  
30 significant variances in activity levels and sleep patterns across frailty categories. Not frail  
31 patients exhibited significantly higher daily steps and active minutes than pre-frail and frail  
32 patients. Not frail patients also had the highest amount of restorative deep and rapid eye  
33 movement sleep. Due to Fitbit methodology and likely frequent interruptions, 28% of the days in  
34 the first month post-transplant had a recorded sleep time of 0 minutes. Although our sample size  
35 was small, our findings underscore the importance of frailty in influencing activity and sleep  
36 patterns among alloHCT recipients.

37 **INTRODUCTION**

38

39 Allogeneic hematopoietic cell transplantation (alloHCT) is a critical treatment for various  
40 hematologic conditions, replacing diseased marrow with healthy stem cells from a donor.  
41 Despite its effectiveness, alloHCT demands significant physiological resilience from patients.  
42 Frailty, a syndrome characterized by a reduction in the body’s physiologic reserve—the ability to  
43 withstand stress and repair tissue damage—is not restricted to older individuals. It also affects  
44 younger patients undergoing alloHCT because of underlying disease or treatment-related  
45 toxicities, leading to an increased risk of mortality and post-transplant complications (1-3).  
46 Frailty presents in physical, psychological, and social dimensions, affecting patients' ability to  
47 cope with and recover from alloHCT. Recognizing the importance of monitoring patient well-  
48 being during treatment, this study employs Fitbit® devices to measure activityx and sleep  
49 patterns—key health indicators during the peri-transplant period (4). While research has  
50 established the detrimental effects of frailty on alloHCT outcomes, the specific activity and sleep  
51 patterns associated with varying degrees of frailty—not frail, pre-frail, and frail—remain  
52 unexplored, particularly in myeloablative alloHCT settings among otherwise fit adults. Our pilot  
53 study aims to investigate these patterns, potentially guiding more personalized care to improve  
54 quality of life and survival for alloHCT recipients.

## 55 **METHODS**

### 56 Patient Selection

57 We included adults ( $\geq 18$  years) scheduled for their first myeloablative alloHCT at the University  
58 of Minnesota who had a smartphone or tablet compatible with the Fitbit® app from June 2022 to  
59 January 2023. Participants received a Fitbit® Sense device before their alloHCT hospitalization  
60 and were advised to stay active by walking within the hospital unit. Access to physical therapists  
61 and exercise facilities was provided. The study adhered to IRB approval and HIPAA guidelines,  
62 with all participants giving written informed consent.

63

### 64 Data Collection and Definitions

65 Participants synced their Fitbit® with a PHI-compliant Fitabase® at least weekly. We included  
66 data from admission until day +30 post-transplant, considering days with  $\geq 10$  hours of wear time  
67 as evaluable days. Activity was measured via daily steps, active and sedentary time—active time  
68 being periods with  $\geq 3$  METS energy expenditure. Sleep analysis included duration, deep sleep,  
69 and REM sleep. Frailty status, assessed pre-transplant using Fried Phenotype criteria (5),  
70 categorized individuals as frail ( $\geq 3$  criteria), pre-frail (1-2 criteria), or not frail (no criteria), with  
71 data extracted from health records.

72

### 73 Statistical Methods

74 Descriptive statistics illustrated Fitbit® data by frailty status. Differences between not frail, pre-  
75 frail, and frail groups were analyzed using Kruskal-Wallis tests and Dunn's multiple

76 comparisons for post hoc assessments. Smoothing spline regression curves show longitudinal  
77 activity and sleep trends. Statistical analyses were completed using JMP Pro 17 (SAS  
78 Corporation, Cary, NC) and GraphPad Prism version 9.4.1 (GraphPad Software, Boston, MA).

79

## 80 **RESULTS**

### 81 Patient Characteristics

82 Nine patients with adequate data were included in the analysis. Median age was 48 (range 22 to  
83 59); five patients were male and four were female. Two patients were categorized as frail, five as  
84 pre-frail, and two as not frail prior to alloHCT. Additional patient characteristics are included in  
85 Supplemental Table 1. The mean percentage of evaluable days between hospital admission to  
86 day +30 was  $81\% \pm 22\%$  with a mean wear time of  $1307 \pm 198$  minutes.

87

### 88 Patterns of Activity

89 Not frail patients had a higher mean of daily steps compared to pre-frail (2.4-fold higher,  $8265 \pm$   
90  $5274$  versus  $3381 \pm 2757$  steps,  $p < 0.0001$ ) and frail (4.2-fold higher,  $1977 \pm 1610$  steps,  $p <$   
91  $0.0001$ ). Pre-frail patients had a higher mean of daily steps than frail (1.7-fold higher,  $p = 0.0103$ ,  
92 Figure 1a). Not frail patients also had a higher mean of active minutes compared to pre-frail ( $56$   
93  $\pm 49$  versus  $20 \pm 26$  minutes,  $p < 0.0001$ ) and frail ( $25 \pm 47$  minutes,  $p < 0.0001$ ). There was no  
94 significant difference in the mean of active minutes between pre-frail and frail patients  
95 ( $p > 0.9999$ ). Not frail patients had a lower mean of sedentary minutes compared to both pre-frail  
96 ( $763 \pm 206$  versus  $884 \pm 313$  minutes,  $p = 0.0064$ ) and frail ( $943 \pm 422$  minutes,  $p = 0.0004$ ).

97 There was no statistically significant difference in the mean sedentary time between pre-frail and  
98 frail patients ( $p=0.2472$ ). Maximum sedentary time occurred around day +15 post-transplant  
99 (Figure 1c).

100

### 101 Patterns of Sleep

102 Across all cohorts, there was a median percentage of 67% (range 0% to 100%) of evaluable days  
103 including complete sleep data with sleep stages from admission to day +30. Overall, not frail  
104 patients had the best sleep quantity and quality (Figure 1b). Not frail patients spent more time in  
105 REM sleep compared to pre-frail ( $52 \pm 36$  versus  $33 \pm 39$  minutes,  $p = 0.0003$ ) and frail ( $24 \pm 43$   
106 minutes,  $p < 0.0001$ ). Frail patients spent less time in deep sleep compared to pre-frail ( $11 \pm 19$   
107 versus  $33 \pm 34$  minutes,  $p = 0.0003$ ) and not frail ( $35 \pm 24$  minutes,  $p < 0.0001$ ). There was a  
108 median percentage of 28% (range 0% to 58%) of days with zero minutes of time asleep, a  
109 median percentage of 36% (range 3% to 87%) of days with zero minutes of time in deep sleep,  
110 and a median percentage of 36% (range 0% to 87%) of days with zero minutes of REM sleep as  
111 measured by the Fitbit®. The sleep time nadir was also around day +15 post-transplant (Figure  
112 1c).

## 113 **DISCUSSION**

114 Our study delineates the variances in activity and sleep patterns among three distinct frailty  
115 phenotypes prior to transplantation. We discovered that patients without frailty exhibit higher  
116 daily step counts and more active time than their pre-frail and frail counterparts. Furthermore,  
117 individuals classified as frail not only engaged in less physical activity but more surprisingly also  
118 experienced diminished durations of restorative deep and REM sleep. The occurrence of days  
119 without recorded sleep data suggests that sleep disruptions are prevalent across all patient  
120 groups. Such disturbances may be partly explained by the Fitbit®'s methodology, which only  
121 logs sleep after an hour without movement and requires a three-hour minimum of sleep data to  
122 analyze sleep stages (6, 7). The frequent nighttime awakenings, as reported by El Jurdi et al.,  
123 averaging 4.5 interruptions per night, are a probable factor in the poor sleep quality captured in  
124 our findings (4).

125

126 Previous research has linked frailty to decreased overall survival, increased non-relapse  
127 mortality, and a decline in the quality of life (2, 3, 8, 9). The reduced activity and lack of  
128 restorative sleep observed in frail patients are likely contributing to these negative health  
129 outcomes. Interventions tailored to the specific aspects of frailty in the elderly have been shown  
130 to enhance physical condition, as noted by Cameron et al. (10). This insight opens the possibility  
131 of applying similar targeted interventions to alloHCT patients, employing pre-transplant frailty  
132 assessments to inform and customize therapeutic strategies, potentially mitigating the impact of  
133 frailty on post-transplant recovery and long-term well-being.

134

135 **CONCLUSION**

136 Our study demonstrated a reduced level of physical activity and poor sleep in individuals with  
137 frailty undergoing myeloablative alloHCT. Recognizing these differences may allow for  
138 development of targeted interventions to reduce disease burdens of care and improve support  
139 systems.




140 **FIGURES**

141

142 **Figure 1:** Patterns of (A) activity and (B) sleep based on phenotype of Frailty. The top of the bar  
143 represents the mean with error bars representing standard deviation. Longitudinal sedentary time  
144 and minutes asleep by transplant date are shown in C, with the line representing the smoothing  
145 spline regression curves.

146



147

148 **REFERENCES**

149

- 150 1. Xue QL. The frailty syndrome: definition and natural history. *Clin Geriatr Med.*  
151 2011;27(1):1-15.
- 152 2. Arora M, Sun CL, Ness KK, Teh JB, Wu J, Francisco L, et al. Physiologic Frailty in  
153 Nonelderly Hematopoietic Cell Transplantation Patients: Results From the Bone Marrow  
154 Transplant Survivor Study. *JAMA Oncol.* 2016;2(10):1277-86.
- 155 3. Pamukcuoglu M, Bhatia S, Weisdorf DJ, DeFor TE, Ustun C, Nayar M, et al.  
156 Hematopoietic Cell Transplant-Related Toxicities and Mortality in Frail Recipients. *Biol*  
157 *Blood Marrow Transplant.* 2019;25(12):2454-60.
- 158 4. El Jurdi N, Nock N, Fu P, Cao S, Cotton JM, Ali N, et al. Physical Activity and Sleep  
159 Measures Using a Fitness Tracking Device during Hematopoietic Cell Transplantation: A  
160 Pilot Study. *Transplant Cell Ther.* 2021;27(6):502.e1-.e6.
- 161 5. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in  
162 older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci.*  
163 2001;56(3):M146-56.
- 164 6. How do I track my sleep with my Fitbit device? [Available from:  
165 [https://help.fitbit.com/articles/en\\_US/Help\\_article/1314.htm?Highlight=sleep%20.](https://help.fitbit.com/articles/en_US/Help_article/1314.htm?Highlight=sleep%20.)]
- 166 7. What should I know about Fitbit sleep stages? [Available from:  
167 [https://help.fitbit.com/articles/en\\_US/Help\\_article/2163.htm?Highlight=sleep%20.](https://help.fitbit.com/articles/en_US/Help_article/2163.htm?Highlight=sleep%20.)]
- 168 8. Mohanraj L, Sargent L, Elswick RK, Toor A, Swift-Scanlan T. Factors Affecting Quality  
169 of Life in Patients Receiving Autologous Hematopoietic Stem Cell Transplantation.  
170 *Cancer Nurs.* 2022;45(2):E552-E9.
- 171 9. Huan-Tze L, Yun-Ru L, Kuan-Der L, Huey-En T. Frailty in chronic myeloid leukemia:  
172 evidence from 2016–2018 Nationwide Inpatient Sample of the US. *BMC Geriatrics.*  
173 2023;23(1).
- 174 10. Cameron ID, Fairhall N, Langron C, Lockwood K, Monaghan N, Aggar C, et al. A  
175 multifactorial interdisciplinary intervention reduces frailty in older people: randomized  
176 trial. *BMC Medicine.* 2013;11(1):65.

177

178

179

